Statement of Changes in Beneficial Ownership (4)
March 09 2020 - 4:19PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Kim Jong Joseph |
2. Issuer Name and Ticker or Trading Symbol
INOVIO PHARMACEUTICALS, INC.
[
INO
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer |
(Last)
(First)
(Middle)
660 W. GERMANTOWN PIKE SUITE 110 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/5/2020 |
(Street)
PLYMOUTH MEETING, PA 19462
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 3/5/2020 | | M | | 120100 | A | (1) | 1220807 | D | |
Common Stock | 3/5/2020 | | F(2) | | 37371 | D | $9.80 | 1183436 | D | |
Common Stock | 3/8/2020 | | M | | 63700 | A | (3) | 1247136 | D | |
Common Stock | 3/8/2020 | | F(4) | | 27697 | D | $14.09 | 1219439 | D | |
Common Stock | | | | | | | | 816527 | I | By Family Limited Partnership |
Common Stock | | | | | | | | 33563 | I | By Daughter: EK |
Common Stock | | | | | | | | 33775 | I | By Son: JK1 |
Common Stock | | | | | | | | 5975 | I | By Spouse |
Common Stock | | | | | | | | 33533 | I | By Son: JK2 |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Restricted Stock Unit | (1) | 3/5/2020 | | M | | | 120100 | (1) | (1) | Common Stock | 120100.0 | $0 (1) | 120100 | D | |
Restricted Stock Unit | (3) | 3/8/2020 | | M | | | 63700 | (3) | (3) | Common Stock | 63700.0 | $0 (3) | 127400 | D | |
Explanation of Responses: |
(1) | Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares vested on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. |
(2) | The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. |
(3) | Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares vested on March 8, 2020; 63,700 shares will vest on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
(4) | The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Kim Jong Joseph 660 W. GERMANTOWN PIKE SUITE 110 PLYMOUTH MEETING, PA 19462 | X |
| Chief Executive Officer |
|
Signatures
|
/s/ Jong Joseph Kim | | 3/9/2020 |
**Signature of Reporting Person | Date |
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024